2024
Modeling the Determinants of Subjective Well-Being in Schizophrenia
Jeong J, Kim J, Kang N, Ahn Y, Kim Y, Lee D, Kim H. Modeling the Determinants of Subjective Well-Being in Schizophrenia. Schizophrenia Bulletin 2024, sbae156. PMID: 39255414, DOI: 10.1093/schbul/sbae156.Peer-Reviewed Original ResearchObsessive-compulsive symptomsSubjective well-beingDeterminants of subjective well-beingLevels of subjective well-beingStructural equation modelingPsychotic symptomsPrediction of subjective well-beingNeuroleptic Treatment ScaleTreatment of schizophreniaMediation of depressionStructural equation modeling analysisCut-off scoreWell-beingMaintained 6 monthsSchizophrenia treatmentCognitive deficitsSchizophreniaReduce distressTreatment ScaleRelationship patternsArea under the curveSomatizationDepressionEquation modelingIndirect effectsComparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study
Kang N, Yoon H, Kim H, Jeong J, Kim M, Kwon J. Comparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study. Psychiatry Investigation 2024, 21: 311-320. PMID: 38569589, PMCID: PMC10990625, DOI: 10.30773/pi.2023.0413.Peer-Reviewed Original ResearchMirror-image studyMaintenance treatmentTreatment-resistant schizophreniaFormulation of clozapineLong-term maintenance treatmentConcentration-to-dose ratioClozapine useGeneric clozapineClozapineClozarilPsychiatric hospitalNo significant differenceSchizophreniaKorean patientsMedical records of patientsClinical insightsBlood test findingsElectronic medical records of patientsSignificant differenceRecords of patientsBrand-name formulationConcomitant medicationsCo-medicationHospitalization durationLaboratory findings
2009
Changes in Neurocognitive Function in Patients With Schizophrenia After Starting or Switching to Amisulpride in Comparison With the Normal Controls
Ahn Y, Lee K, Kim C, Kim J, Kang D, Jun T, Choi J, Chung I, Kim H, Hwang S, Kim Y. Changes in Neurocognitive Function in Patients With Schizophrenia After Starting or Switching to Amisulpride in Comparison With the Normal Controls. Journal Of Clinical Psychopharmacology 2009, 29: 117-123. PMID: 19512972, DOI: 10.1097/jcp.0b013e31819a6995.Peer-Reviewed Original ResearchConceptsNormal controlsNeurocognitive functionPP analysisControl groupSecond-generation antipsychoticsEffect sizeHealthy control groupNeurocognitive function testsLong-term improvementComposite effect sizeFunction testsPatient groupMedication effectsTrail Making TestPatientsCognitive improvementPractice effectsSchizophreniaTest batteryRelative effect sizesITTMost measuresGroupAntipsychoticsAmisulpride